🔗 Share this article

As the US continues making unprecedented changes to its vaccination schedules, an unexpected name appears somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports physician and epidemiologist who first made her name by casting doubt on Covid vaccines in the global health crisis and has focused upon possible deaths following Covid immunization in her recent position at the Food and Drug Administration.

Planned Changes to Childhood Immunization Program

Health officials planned to unveil sweeping changes to the pediatric vaccine schedule in December, bringing the US with Denmark’s vaccine program, sources say – a substantial departure that would place the US out of step with many the world with no evidence for public health gain. The planned update has been postponed until the coming year.

Instead of the top vaccines chief, Dr. Høeg is scheduled to address the audience at the gathering. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the office this calendar year.

Consolidating Power at the FDA

This interim role might represent a closer partnership between the drug and vaccine centers as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it suggests a renewed priority upon dismantling long-standing vaccines at the FDA.

Høeg has often pushed for discontinuing certain childhood vaccine recommendations in the US in order to be more like Denmark's approach, a society with comprehensive healthcare and a population about the population of Wisconsin’s.

To date public appearances, she has continued to focus on vaccines – traditionally the purview of Prasad, director of the FDA’s CBER – instead of medication approval.

Concerns Over Background

Dr. Høeg has no apparent experience in pharmaceutical research, approval processes or management, which has been standard for past heads of the CBER. She has worked at the FDA as a senior adviser to the FDA chief and the vaccine center since March.

“She appears not to have the necessary background” for running the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in managing a sizeable institution. She lacks background in industry regulation.”

Past commissioners of CBER would “be deeply familiar with legal statutes and the research of pharmaceutical innovation”, noted a former acting FDA commissioner. “Clearly, she doesn’t have the type of experience that previous people who led the center have had.”

This division has an vast range of responsibilities at the agency, she emphasized.

“The public just zeroes in on the innovative therapies, but the generic drug division clears numerous generic medications. There’s a biosimilars program, OTC medication office and other areas, and every single one need to be managed,” Dr. Woodcock said. “The responsibility you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a major management aspect to the job, which manages over 5,000 staff members. “It’s a massive leadership role, if you perform it correctly,” the former official concluded.

Agency Reaction and Controversial Policies

When asked about questions about Dr. Høeg's qualifications and whether this appointment signifies greater collaboration among agency officials on vaccines, a press secretary stated that the “concerns stem from inaccurate assumptions”.

“Her experience is consistent with the responsibilities of her job,” the representative explained, citing the time Høeg spent advising the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg inherits the agency head's controversial expedited review system, a controversial rapid drug-approval program that apparently concerned her former heads. “By what process are these therapies being picked for this voucher program? Who is making the decisions?” Dr. Howard asked. “There is a lot of lack of transparency happening at the FDA right now.”

Overall, he said, “the FDA looks to be trending towards less stringent regulations of pharmaceuticals, except for vaccines.”

Documented History on Vaccines

Concerning immunizations, Dr. Høeg has a clearer, if concerning, history, some experts have noted. She released a study using non-validated volunteer-provided data to determine the frequency of heart inflammation following Covid immunization. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who reportedly have altered data to suggest Covid vaccinations are pose a greater threat than they are.

Among her “wish list” for the incoming federal leadership encompassed altering guidelines for novel immunizations and halting “optional” immunizations, she said after the election on a audio program. At the FDA, Dr. Høeg has allegedly suggested barring adolescent males from receiving Covid vaccines.

“She is an complete true believer who begins with her conclusions and tailors the evidence to accommodate the science in a very deceptive, fraudulent manner,” Dr. Howard said.

Taking Control and a “Push for Payback”

Høeg joined fellow contrarians, {like|